Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance

Metabolism: Clinical and Experimental

Volumn 57, Issue 10, 2008, Pages 1473-1478

  Makita, Shinji ^a   Abiko, Akihiko ^a   Naganuma, Yujirou ^a   Moriai, Yoshiteru ^a   Nakamura, Motoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; TELMISARTAN;

ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BODY WEIGHT; C-REACTIVE PROTEIN; CHOLESTEROL; FEMALE; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; INSULIN; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; TRIGLYCERIDES;

EID: 51649094297     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.05.019     Document Type: Article

References (32)

1. Chandran M., Phillips S.A., Ciaraldi T., and Henry R.R. Adiponectin: more than just another fat cell hormone?. Diabetes Care 26 (2003) 2442-2450
2. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
3. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
4. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
5. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
6. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 6 (2005) 7-14
7. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
8. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
9. Yusuf S., Ostergren J.B., Gerstein H.C., Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112 (2005) 48-53
10. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 30 (2004) 487-496
11. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-y activity. Circulation 109 (2004) 2054-2057
12. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension 43 (2004) 993-1002
13. Shimabukuro M., Tanaka H., and Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25 (2007) 841-848
14. Sugimoto K., Qi N.R., Kazdova L., Pravenec M., Ogihara T., and Kurtz T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47 (2006) 1003-1009
15. Araki K., Masaki T., Katsuragi I., Tanaka K., Kakuma T., and Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48 (2006) 51-57
16. Sharma A.M., Janke J., Gorzelniak K., Engeli S., and Luft F.C. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40 (2002) 609-611
17. Gorzelniak K., Engeli S., Janke J., Luft F.C., and Sharma A.M. Hormonal regulation of the human adipose-tissue rennin-angiotensin system: relationship to obesity and hypertension. J Hypertens 20 (2002) 965-973
18. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPAR gamma ligands increase expression and plasma concentrations of adiponectin an adipose derived protein. Diabetes 50 (2001) 2094-2099
19. Vitale C., Mercuro G., Castiglioni C., Cornoldi A., Tulli A., Fini M., et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4 (2005) 6
20. Clasen R., Schupp M., Foryst-Ludwig A., Sprang C., Clemenz M., Krikov M., et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46 (2005) 137-143
21. Miura Y., Yamamoto N., Tsunekawa S., Taguchi S., Eguchi Y., Ozaki N., et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 28 (2005) 757-758
22. Watanabe S., Okura T., Kurata M., Irita J., Manabe S., Miyoshi K., et al. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther 28 (2006) 1677-1685
23. Nomura S., Shouzu A., Omoto S., Nishikawa M., Fukuhara S., and Iwasaka T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 117 (2006) 385-392
24. Zorad S., Dou J.T., Benicky J., Hutanu D., Tybitanclova K., Zhou J., et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 552 (2006) 112-122
25. Makita S., Abiko A., Naganuma Y., Moriai Y., and Nakamura M. Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients. Cardiovasc Drugs Ther 21 (2007) 317-318
26. Mori Y., Itoh Y., and Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 20 (2007) 431-436
27. Bluher M., Bullen Jr. J.W., Lee J.H., Kralisch S., Fasshauer M., Kloting N., et al. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 91 (2006) 2310-2316
28. Yang W.S., Lee W.J., Funahashi T., Tanaka S., Matsuzawa Y., Chao C.L., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86 (2001) 3815-3819
29. Mori Y., Itoh Y., Obata T., and Tajima N. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine 29 (2006) 143-148
30. Derosa G., Ragonesi P.D., Mugellini A., Ciccarelli L., and Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 27 (2004) 457-464
31. Bahadir O., Uzunlulu M., Oguz A., and Bahadir M.A. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 30 (2007) 49-53
32. Janke J., Schupp M., Engeli S., Gorzelniak K., Boschmann M., Sauma L., et al. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 24 (2006) 1809-1816